BioCentury
ARTICLE | Company News

FDA to review Biogen Idec's hemophilia B therapy

March 5, 2013 2:12 AM UTC

Biogen Idec Inc. (NASDAQ:BIIB) said FDA accepted for review a BLA for rFIXFc to treat hemophilia B. Biogen Idec said the application was submitted during 4Q12; a standard review would place the PDUFA ...